Cancer, a significant cause of mortality, necessitates improved drug delivery strategies. Exosomes, as natural drug carriers, offer a more efficient, targeted, and less toxic drug delivery system compared to direct dispersal methods via ingestion or injection. To be successfully implemented as drug carriers, efficient loading of drugs into exosomes is crucial, and a deeper understanding of the loading mechanism remains to be solved. This study introduces surface-enhanced Raman scattering (SERS) to monitor drug loading efficacy at the single vesicle level. By enhancing the Raman signal, SERS overcomes limitations in Raman spectroscopy. A gold nanopyramids array-based SERS substrate assesses exosome heterogeneity in drug-loading capabilities with the help of single-layer graphene for precise quantification. This research advances targeted drug delivery by presenting a more efficient method of evaluating drug-loading efficiency into individual exosomes through SERS-based monitoring. Furthermore, the study explores leveraging osmotic pressure variations, enhancing the efficiency of drug loading into exosomes.
Surface-enhanced Raman spectroscopy (SERS) is a powerful tool for elucidating the molecular makeup of materials. It possesses the unique characteristics of single-molecule sensitivity and extremely high specificity. However, the true potential of SERS, particularly in capturing the biochemical content of particles, remains underexplored. In this study, we harnessed transformer neural networks to interpret SERS spectra, aiming to discern the amino acid profiles within proteins. By training the network on the SERS profiles of 20 amino acids of human proteins, we explore the feasibility of predicting the predominant proteins within the µL-scale detection volume of SERS. Our results highlight a consistent alignment between the model’s predictions and the protein’s known amino acid compositions, deepening our understanding of the inherent information contained within SERS spectra. For instance, the model achieved low root mean square error (RMSE) scores and minimal deviation in the prediction of amino acid compositions for proteins such as Bovine Serum Albumin (BSA), ACE2 protein, and CD63 antigen. This novel methodology offers a robust avenue not only for protein analytics but also sets a precedent for the broader realm of spectral analyses across diverse material categories. It represents a solid step forward to establishing SERS-based proteomics.
This protocol outlines a comprehensive, label-free platform that integrates surface-enhanced Raman spectroscopy (SERS) with machine learning (ML) to detect and molecularly profile individual small extracellular vesicles (sEVs) for diagnostic and therapeutic applications. The method begins with sEV isolation using either size exclusion chromatography or ultracentrifugation. Isolated vesicles are then analyzed on engineered plasmonic gold nanopyramid 2D array substrates capable of single-vesicle sensitivity. By leveraging intrinsic Raman biochemical fingerprints, the protocol enables high-specificity detection without external labels. Following spectral acquisition, data undergo preprocessing and are analyzed using trained machine learning algorithms (e.g., LDA, SVC) to classify disease states, successfully distinguishing gastric cancer from healthy controls using sEVs from tissue, plasma, and saliva with respective classification accuracies of 90.1%, 70.9%, and 60.7%. Additionally, its therapeutic application is shown by quantifying doxorubicin loading in single sEVs, a measurement enhanced by using graphene-coated substrates as an internal standard. This approach allows for high-throughput analysis that captures population heterogeneity essential for early disease detection and understanding drug loading efficiency at the single-vesicle level.
13 March 2026 in Journal of Visualized Experiments
This protocol outlines a comprehensive, label-free platform that integrates surface-enhanced Raman spectroscopy (SERS) with machine learning (ML) to detect and molecularly profile individual small extracellular vesicles (sEVs) for diagnostic and therapeutic applications. The method begins with sEV isolation using either size exclusion chromatography or ultracentrifugation. Isolated vesicles are then analyzed on engineered plasmonic gold nanopyramid 2D array substrates capable of single-vesicle sensitivity. By leveraging intrinsic Raman biochemical fingerprints, the protocol enables high-specificity detection without external labels. Following spectral acquisition, data undergo preprocessing and are analyzed using trained machine learning algorithms (e.g., LDA, SVC) to classify disease states, successfully distinguishing gastric cancer from healthy controls using sEVs from tissue, plasma, and saliva with respective classification accuracies of 90.1%, 70.9%, and 60.7%. Additionally, its therapeutic application is shown by quantifying doxorubicin loading in single sEVs, a measurement enhanced by using graphene-coated substrates as an internal standard. This approach allows for high-throughput analysis that captures population heterogeneity essential for early disease detection and understanding drug loading efficiency at the single-vesicle level.